News
PGEN
1.390
0.00%
0.000
Weekly Report: what happened at PGEN last week (0513-0517)?
Weekly Report · 1d ago
AquaBounty Technologies Inc reports results for the quarter ended in March - Earnings Summary
AquaBounty Technologies Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of $ per share. Revenue rose 20% to $ thousand from the same quarter last year. The average analyst rating on the company's shares is "hold"
Reuters · 6d ago
Cantor Fitzgerald Reiterates Overweight on Precigen
Benzinga · 6d ago
Precigen Price Target Maintained With a $7.00/Share by Stifel
Dow Jones · 6d ago
Precigen Is Maintained at Buy by Stifel
Dow Jones · 6d ago
Precigen Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Reiterates Buy on Precigen, Maintains $6 Price Target
Benzinga · 6d ago
Buy Rating Affirmed for Precigen Amid Promising Clinical Data and Strong Financial Outlook
Swayampakula Ramakanth maintained the Buy rating on Precigen (PGEN) with a price target of $20. The company is a biotechnology company developing treatments for cancer and other diseases. The FDA is expected to approve PRGN-2012 in the near future.
TipRanks · 6d ago
Buy Rating Affirmed for Precigen Amid Promising Clinical Developments and Strategic FDA Alignment
TipRanks · 05/15 04:35
Precigen, Inc. Quarterly Report for the Period Ended March 31, 2024
Press release · 05/15 02:27
Precigen Inc: Quarterly report
Press release · 05/15 01:51
PGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q1 2024
Precigen reported earnings per share of -10 cents for the first quarter of 2024. The company reported revenue of $ million. This was below the analyst estimate for revenue of $10 million. Precigen also reported results for the fourth quarter of 2015.
Investorplace · 05/15 00:53
Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates
NASDAQ · 05/14 21:20
Notable earnings after Tuesday's close
Major earnings expected after the bell on Tuesday include: Oxford Lane Capital Corp. And Seadrill Limited. Other major earnings slated for release after Tuesday's close include: Canoo and Canoo. The full earnings season calendar can be found at Seeking Alpha's Earnings season calendar.
Seeking Alpha · 05/13 21:35
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
NASDAQ · 05/13 21:10
Weekly Report: what happened at PGEN last week (0506-0510)?
Weekly Report · 05/13 09:24
Precigen, Inc.'s (NASDAQ:PGEN) Path To Profitability
Precigen, Inc. Operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies. The company announced a latest loss of US$96m for its most recent financial year. Analysts expect the company to grow 55% year-on-year to become profitable by 2026. Precigen is on the verge of breakeven and is expected to grow to US$80m in 2026 .
Simply Wall St · 05/11 14:58
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), Nevro Corp (NVRO) and Precigen (PGEN)
TipRanks · 05/08 05:10
Weekly Report: what happened at PGEN last week (0429-0503)?
Weekly Report · 05/06 09:25
AquaBounty Technologies Inc <AQB.OQ> expected to post a loss of $1.52 a share - Earnings Preview
AquaBounty Technologies Inc. Expected to post a loss of $1.52 a share. The company is expected to report a 25.7% increase in quarterly revenue to $500 thousand from $397.85 thousand. The Harvard Massachusetts-based company will report results on May 2.
Reuters · 04/30 15:40
More
Webull provides a variety of real-time PGEN stock news. You can receive the latest news about Precigen Inc through multiple platforms. This information may help you make smarter investment decisions.
About PGEN
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.